CytRx reports preliminary efficacy results of bafetinib

9th October 2011 (Last Updated October 9th, 2011 18:30)

The CytRx ENABLE Phase II clinical trial has demonstrated positive results for bafetinib, a Bcr-Abl, Lyn and Fyn kinase inhibitor for the treatment relapsed or refractory B-cell chronic lymphocytic leukaemia (B-CLL).

The CytRx ENABLE Phase II clinical trial has demonstrated positive results for bafetinib, a Bcr-Abl, Lyn and Fyn kinase inhibitor for the treatment relapsed or refractory B-cell chronic lymphocytic leukaemia (B-CLL).

The trial involves 18 patients who self-administer bafetinib twice daily, and continue treatment as long as their cancer is controlled and no intolerable side effects occur.

The preliminary results from the study demonstrated that bafetinib was clinically active in a group of patients with B-CLL who have failed several other treatments for their cancer.

CytRx president and CEO Steven Kriegsman said the study allows them to assess preliminary efficacy and safety results following trial initiation before potentially moving into larger clinical trials.

"Earlier this year we reported favourable preliminary results from the ENABLE trial, and believe that our drug candidate's unique kinase inhibitor formulation could be efficacious in treating B-CLL and other cancers where approved therapies have failed," Kriegsman added.